Medical Diagnostics News

Showcase

BOC Sciences Becomes the Largest PseudoUridine Supplier in the World

BOC Sciences recently announces that its annual yield of pseudoUridine has reached more than 500 kilograms, which indicates that this US-based chemical and pharmaceutical company has become the largest supplier of pseudoUridine in the world. Currently, due to the severe situation of the COVID-19 pandemic, the global need for vaccines is still huge. Under this circumstance, BOC Sciences has ...

Sep. 16, 2021

By BOC Sciences

Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin

Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including Moderna Divestment of Specialty Ingredients ...

Sep. 16, 2021

By Lonza Group Ltd

Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research

Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...

Sep. 1, 2021

By Creative Biolabs

Recruitment of the smallest infants in the Connection study paused

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...

Aug. 25, 2021

By Infant Bacterial Therapeutics AB

Creative Proteomics Announces the Launch of Its New Metabolomics Division

Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and ...

Aug. 23, 2021

By Creative Proteomics

Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers

Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. ...

Aug. 23, 2021

By Creative Proteomics

MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine

MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics has recently announced microbial therapeutics ...

Aug. 19, 2021

By CD Genomics

CD Genomics Launched HLA Genotyping Service to Help Scientists Better Understand the Mechanisms of MHC

CD Genomics is one of the leading service providers in the area of genomic sequencing and data analysis as well as other genomic-related technologies to fully supports customers’ research projects. HLA genotyping service is one such. CD Genomics provides accurate and reliable HLA genotyping service based on next-generation sequencing (NGS) technology that generates unambiguous, ...

Aug. 19, 2021

By CD Genomics

Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics. Recently, the company ...

Aug. 18, 2021

By Creative Proteomics

Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an ...

Aug. 10, 2021

By Second Genome Therapeutics

Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in ...

Aug. 5, 2021

By Second Genome Therapeutics

New SARS CoV-2 AG Test Kit available!

Have your employees tested regularly! With this new test you will be reliably informed about possible COVID-19 infections in your company. Email our sales team sales@cardimed.nl today! Fast and highly efficient Covid-19 yes/no infection test. A positive or negative result can be determined after only 15 minutes. Sensitivity of 98.32% (CT Specificity is 100% for both CE ...

Aug. 5, 2021

By CARDIMED B.V.

SARS-Cov-2 Antigen Rapid Test Kits

CARDIMED B.V. is the official distributor for the SARS-Cov-2 Antigen Rapid Test Kits (Lepu Medical) in the Netherlands. The advantages at a glance: Non-invasive Easy to use Convenient, no equipment required Fast, get a result in 15 minutes Stable, with high accuracy Cost-effective, cost-efficient The test card contains a gold-labeled novel coronavirus N protein monoclonal antibody pre-coated ...

Aug. 5, 2021

By CARDIMED B.V.

Christie Med Announces New Authorized Partner in Al Zahrawi for UAE Distribution of VeinViewer

As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the-USA, VeinViewer® Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of ...

Jul. 28, 2021

By Christie Medical Holdings, Inc.

Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin

Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including Moderna Divestment of Specialty Ingredients ...

Jul. 23, 2021

By Lonza Group Ltd

Creative Proteomics Launches Complete Product Portfolio for Lipidomics Research Solutions

Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population ...

Jul. 23, 2021

By Creative Proteomics

Creative Proteomics Announces the Launch of Its New Metabolomics Division

Creative Proteomics is an integrated company that provides proteomics, metabolomics, glycomics, and bioinformatics analysis services to researchers in the pharmaceutical, biotechnology, agriculture and nutrition industries, as well as academic and government organizations. With the aim of developing efficient metabolomics services to better support customer’s research, after hard work and ...

Jul. 23, 2021

By Creative Proteomics

Creative Proteomics Releases Quantitative Proteomics Platform Based on SILAC Technology

Creative Proteomics has more than 10 years of experience with providing advanced proteomics services to customers in many countries and regions. Creative Proteomics has a quantitative proteomics research platform based on SILAC technology, which provides an effective solution for comprehensive and systematic qualitative and quantitative analysis of complex mammalian cell proteomics. ...

Jul. 23, 2021

By Creative Proteomics

Kurin, Inc. announces results on Kurin efficacy from Oishei Children`s Hospital with zero blood culture

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture ...

Jul. 21, 2021

By Kurin, Inc.

Creative Proteomics Launches Complete Product Portfolio for Lipidomics Research Solutions

Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population ...

Jul. 21, 2021

By Creative Proteomics